Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes

Table 1 Clinical, Cytogenetics and Pathological Data

Number of patients	30
Gender (M/F)	18/12
Age at study, range (median)	19-87 (64 yr)
Peripheral blood values (n = 29)
WBC* (K/CMM) range (median)	1.2 - 45.5 (3.1)
Hb* (g/dl) range (median)	7.4-15.6 (9.8)
Platelet* (K/CMM) range (median)	14 - 598 (82)
Eosinophils* % range (median)	0-9.2 (1.3)
Bone marrow blasts, range (median)	0-31% (8.0%)
Cellularity
Hypercellular	17
Normocellular	7
Hypocellular	4
Fibrotic or aparticulate	2
FAB^#
RA	1
RARS	2
RAEB	15
RAEB-t	5
Refractory cytopenia, NOS	2
Hypoplastic MDS	1
MDS, NOS	1*
MPN → AML	1
Idiopathic myelofibrosis	1
Abnormal cytogenetics	1
WHO
5q-syndrome	1
RARS	1
RCMD	2
RAEB-1	2
RAEB-2	8
AML	3
t-MDS	8
t-AML	2**
Other pathology
AA/hypoplastic MDS	1
Primary myelofibrosis	1
Cytogenetic abn only^	1
IPSS score - for 16 patients
HIGH	2
INT-2	10
INT-1	2
LOW	2
History of previous chemo- or radiotherapy	14^

# Samples were submitted with a working diagnosis of MDS. Pathology review revealed the myeloid diagnoses presented in this table. *Aspirate was aparticulate and hemodilute (insufficient for pathology review). **Blast percentage between 22-31% when sample underwent morphologic evaluation. ^Patients were previously treated for AML (4), MDS (1), Hodgkin lymphoma (3), non-lymphoma (3), breast cancer (1), prostate (1), and prostate/kidney cancer (1).

ISSN: 1755-8166